<DOC>
	<DOC>NCT01519700</DOC>
	<brief_summary>The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.</brief_summary>
	<brief_title>Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1. Patients with histologically proven breast cancer, eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy 2. Women â‰¥ 18 years of age 3. Estimated life expectancy of more than six months 1. Previous or concurrent malignancy except noninvasive nonmelanoma skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least ten years prior to study entry 2. Any serious illness or medical condition that may interfere with safety, compliance, response to the products under investigation and their evaluation, e.g.: Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF, neutropenia</keyword>
	<keyword>supportive care</keyword>
	<keyword>breast cancer</keyword>
</DOC>